



CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)

Short profile

Triox Nano Ltd

Medical field	Oncology / Gynecology/ Urology
Product (name and type)	TXN770, Biopharmaceuticals
Growth stage	Positioning for Scale, Preclinical; FDA pre-IND stage, toxicology study expected to start in Q4/2020
Founders	Roy Farfara (Founder, CTO)

Description of product:

TXN770, a 150nm silica nanoparticle loaded with doxorubicin, has been developed by Triox Nano under its S.M.A.R.T programmable nanoparticle technology. S.M.A.R.T is a hybrid technology based on programmable DNA capped MSNP (mesoporous silica nano particles) designed to deliver different chemo agents selectively to tumors and metastases decreasing its toxicity in healthy tissues.

Project goal:

The locally high concentration of chemotherapy transferred via TXN770 to the tumor cells will enable better clinical results while toxicity of chemotherapy remains low with a low concentration in healthy tissues. FDA clearance for TXN770

Project type:

The company searches for Charité partners to validate the safety and pharmacokinetics of TXN770 as a treatment for metastatic Triple Negative Breast Cancer (TNBC) patients who failed at least 3 other treatment lines, while a byproduct result may allow to validate TXN770's efficacy. In a second phase, efficacy in lung metastatic patients and general metastatic patients shall be proven.

Estimated Trial Duration: 12 Months, Estimated Project Duration: 24-36 Months



Eligible by the IIA



Roy@trioxnano.com



Roy Farfara: +972-544597704



Smartriox.com

